Stockscreener 앱 받기
2.82
4.44%
0.12
전일 마감가:
$2.70
열려 있는:
$2.73
하루 거래량:
9,651
Relative Volume:
0.19
시가총액:
$12.27M
수익:
$1.41M
순이익/손실:
$-9.84M
주가수익비율:
-1.3173
EPS:
-2.1408
순현금흐름:
$-7.85M
1주 성능:
+0.00%
1개월 성능:
-9.62%
6개월 성능:
-9.32%
1년 성능:
-29.15%
1일 변동 폭
$2.6486
$2.82
1주일 범위
$2.6486
$2.92
52주 변동 폭
$2.15
$4.56
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Compare BLRX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
2.82 | 12.26M | 1.41M | -9.84M | -7.85M | -2.1408 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2017-05-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-02-13 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-08-17 | 재확인 | Maxim Group | Buy |
| 2015-07-27 | 재확인 | ROTH Capital | Buy |
| 2015-06-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스
Price to sales forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
BioLineRx, Hemispherian to present GLIX1 data at ESMO 2026 - Investing.com
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 - Sahm
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
Enterprise value to revenue forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx reports preclinical data on GLIX1 with PARP inhibitor - Investing.com
BioLineRx and Hemispherian Report GLIX1–PARP Synergy in Ovarian Cancer Model, Plan Trial Expansion - TipRanks
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
A41038 Forecast — Price Target — Prediction for 2027 - TradingView
BLRX Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze - The Globe and Mail
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
BioLineRx shares rise 4% on first patient dosed in cancer trial - Investing.com
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results - Investing.com
BioLineRx shares rise 4% on first patient dosed in cancer trial By Investing.com - Investing.com South Africa
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend - TipRanks
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
BLRXBioline Rx Ltd ADR Stock Price and Quote - Finviz
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls - TipRanks
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Barchart.com
BLRX Technical Analysis | Trend, Signals & Chart Patterns | BIOLINERX LTD-SPONS ADR (NASDAQ:BLRX) - ChartMill
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Morningstar
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma - TipRanks
BioLineRx reports preclinical data for GBM treatment GLIX1 - Investing.com
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - Barchart.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Number of shareholders of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial - TipRanks
BioLineRx doses first patient in glioblastoma drug trial By Investing.com - Investing.com South Africa
BioLineRx doses first patient in glioblastoma drug trial - Investing.com
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Barchart.com
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target - TipRanks
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
Operating cash flow per share of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx launches trial of brain cancer drug GLIX1 By Investing.com - Investing.com South Africa
BioLineRx initiates Phase 1/2a study of GLIX1 - tipranks.com
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Finviz
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma - TipRanks
BioLineRx launches trial of brain cancer drug GLIX1 - investing.com
BioLineRx provides corporate update - tipranks.com
Bioline Rx Ltd Adr (BLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):